AbbVie shares weekly forecast: Recovery holds but faces a stretched setup

Traders Union
All News
Stocks
AbbVie gains 6.43% this week

Highlights

Shares of AbbVie rose 6.43% over the past week to $265.63, establishing a bullish trend.
Momentum indicators are strong but approaching overbought conditions as the stock trades at the top of its weekly range.
Key support is at $254.34 and resistance at $266.96, with an expected range of $257.08 to $274.66 for the coming week.

Revenue surge and acquisition deal shape flows amid insider activity this week

AbbVie completed a major $8–9 billion unsecured note financing between August 13 and August 19, 2026, to support its pending Apogee Therapeutics acquisition, according to Investing.com and TipRanks. During the same period, the company reported double-digit revenue growth for the second quarter, exceeded sales expectations, and raised its full-year 2026 revenue and earnings guidance, though adjusted EPS was slightly trimmed for potential dilution from the Apogee deal, as highlighted by Trefis and Simply Wall St. Additional developments included a notable insider stock sale by EVP Nicholas Donoghoe on August 18, per TipRanks, as well as a large increase in ABBV holdings by ABN Amro Investment Solutions, according to MarketBeat.

Momentum builds as technical signals near overbought during the week

On the daily chart, the recent move is supported by momentum strength as the stock sits at the top of its weekly range with volatility at 7.71%. The RSI at 67.42 is approaching overbought territory, and Bull/Bear Power signals continued buyer dominance. Support is marked at $254.34 (Ichimoku Kijun), with resistance at $266.96 from the recent weekly high. The momentum character is defined by an emerging move higher that is not yet confirmed, suggesting increased attention is warranted as the trend develops.

Upside breakout risk dominates with range-bound bias for next week

For the coming trading week, the expected range is $257.08 to $274.66. There is a very high probability of an increase and a very low probability of a decrease. The base case favors consolidation or upward drift between $254.34 and $266.96. A clear break above $266.96 would open the path toward $274.66, while a move below $254.34 signals potential downside toward $257.08.

Sholanke Dele, market strategist, sees last week’s strength in AbbVie as sentiment-driven, backed by upbeat deal activity and upgraded guidance. He believes optimism has run hot, but high volatility and the crowded overbought setup point to caution as price tests major resistance. The macro backdrop and recent insider selling underscore risks that may limit follow-through. ‘Until ABBV clearly breaks above $266.96, I expect mostly range-bound action and advise staying defensive this week.’

Earlier, analysts noted that AbbVie's technical strength and strategic acquisitions were positioning the stock for further gains, with a watchful eye on potential overbought conditions. The current setup now adds confirmation through upgraded corporate guidance and robust Q2 performance, highlighting the $266.96 resistance as the next key level to watch for a breakout toward $274.66.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.